Tomotaka Koike

Mr. Tomotaka Koike

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
NYNaoya Yanagi
Naoya Yanagi
TKTomotaka Koike
Tomotaka Koike
KKKentaro Kamiya
Kentaro Kamiya
NHNobuaki Hamazaki
Nobuaki Hamazaki
KNKohei Nozaki
Kohei Nozaki
MAMasayasu Arai
Masayasu Arai
Skeletal muscle wasting in the intensive care unit (ICU) has been associated with mortality, but it is unclear whether sarcopenia, defined by skeletal muscle mass and function, is useful for detailed risk stratification after ICU discharge. In this cohort study, 72 critically ill patients with an ICU stay of ≥48 h were identified. Skeletal muscle mass was assessed from the muscle thickness (MT) of the patients’ quadriceps using ultrasound images before ICU discharge. Skeletal muscle function was assessed from the patients’ muscle strength (MS) before ICU discharge according to the Medical Research Council sum score. A diagnosis of sarcopenia in the ICU was made in patients with low MT and low MS. The study endpoint was 1-year mortality. Sarcopenia in the ICU was diagnosed in 26/72 patients (36%). After adjusting for covariates in the Cox regression, sarcopenia in the ICU was significantly associated with 1-year mortality (hazard ratio 3.82; 95% confidence interval, 1.40–10.42). Sarcopenia in the ICU, defined by low skeletal muscle mass and function, was associated with 1-year mortality in survivors of critical illness. Skeletal muscle mass and function assessed at the bedside could be used to identify higher-risk patients in the ICU.

29 May 2022 in Healthcare
Verified
Journal Article
Open access
PDF file
TKTomotaka Koike
Tomotaka Koike
NHNobuaki Hamazaki
Nobuaki Hamazaki
MKMasayuki Kuroiwa
Masayuki Kuroiwa
KKKentaro Kamiya
Kentaro Kamiya
TOTomohisa Otsuka
Tomohisa Otsuka
MAMasayasu Arai
Masayasu Arai
Few studies have reported on the effectiveness of awake prone therapy in the clinical course of coronavirus disease (COVID-19) patients. This study aimed to investigate the effects of awake prone therapy during spontaneous breathing on the improvement of oxygenation over 3 weeks for COVID-19 acute respiratory failure. Data of consecutive COVID-19 patients with lung disorder with a fraction of inspired oxygen (FIO2) ≥ 0.4 and without tracheal intubation were analyzed. We examined changes in SpO2/FIO2, ROX index ((SpO2/FIO2)/respiratory rate) and the seven-category ordinal scale after the initiation of FIO2 ≥ 0.4 and compared these changes between patients who did and did not receive prone therapy. Of 58 patients, 27 received awake prone therapy, while 31 did not. Trend relationships between time course and change in SpO2/FIO2 and ROX index were observed in both groups, although a significant interaction in the relationship was noted between prone therapy and change in SpO2/FIO2 and ROX index. The seven-category ordinal scale also revealed a trend relationship with time course in the prone therapy group. The awake prone therapy was significantly associated with a lower rate of tracheal intubation. In patients with COVID-19 pneumonia treated with FIO2 ≥ 0.4, awake prone therapy may improve oxygenation within two weeks.

1 January 2016 in Journal of the Japanese Society of Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
YIYoshiaki Iwashita
Yoshiaki Iwashita
SNSatoru Nebuya
Satoru Nebuya
TKTomotaka Koike
Tomotaka Koike
HIHiroshi Imai
Hiroshi Imai